Ozanimod in Relapsing Multiple Sclerosis: Pooled Safety Results From the Clinical Development Program

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients

(2020) Peter Alping et al.   ANNALS OF NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

(2019) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

(2018) Jeffrey A Cohen et al.   Multiple Sclerosis Journal

Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis

(2018) Saifon Chawanpaiboon et al.   Lancet Global Health

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis

(2018) Stuart Cook et al.   Multiple Sclerosis and Related Disorders

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator

(2017) Jonathan Q. Tran et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Trends in Risk of Pregnancy Loss Among US Women, 1990-2011

(2017) Lauren M. Rossen et al.   PAEDIATRIC AND PERINATAL EPIDEMIOLOGY

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

(2016) F L Scott et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implication of sphingosin-1-phosphate in cardiovascular regulation

(2016) Ningjun Li   Frontiers in Bioscience-Landmark

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

(2016) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

(2014) T. Olsson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

(2014) Ludwig Kappos et al.   Multiple Sclerosis and Related Disorders